Highlights of 2024: unleashing the power of NK cells-cancer's worst nightmare.

IF 3.2 4区医学 Q3 CELL BIOLOGY

Immunology & Cell Biology Pub Date : 2025-06-02 DOI:10.1111/imcb.70037

Capucine Bourel, Fernando Souza-Fonseca-Guimaraes, Sylvie Lesage

引用次数: 0

Abstract

In this article for the Highlights of 2024 Series, we discuss strategies to enhance NK cell-based cancer therapies. These include (1) cytokine expression on bacterial membranes to boost NK cell activation in tumors, (2) optimizing CAR-NK cell manufacturing for improved efficacy, (3) using CRISPR-Cas9 to identify and target inhibitory genes, and (4) using tetraspecific engagers to enhance cytotoxicity and cytokine memory-like NK cells strengthening anti-tumor responses. This year's progress holds much promise for cancer treatments exploiting NK cells.

查看原文本刊更多论文

2024年的亮点：释放NK细胞的力量——癌症最可怕的噩梦。

在这篇文章2024系列的亮点中，我们讨论了增强NK细胞为基础的癌症治疗的策略。这些包括(1)在细菌膜上表达细胞因子以促进肿瘤中NK细胞的活化，(2)优化CAR-NK细胞制造以提高疗效，(3)使用CRISPR-Cas9识别和靶向抑制基因，以及(4)使用四特异性参与器增强细胞毒性和细胞因子记忆样NK细胞增强抗肿瘤反应。今年的进展为利用NK细胞治疗癌症带来了很大希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology & Cell Biology 医学-免疫学

CiteScore

7.50

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： The Australasian Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region. It is a broadly based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The Society provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.